

Form PTO-1449

U.S. Department of Commerce

(Rev. 8-83)

Patent and Trademark Office

Atty. Docket No.
2132.022Serial No.
09/940,698

INFORMATION DISCLOSURE CITATION

Applicant
Jackowski et al.

(Use several sheets if necessary)

Filing Date
08/27/2001Group
3736

U. S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	Name	Class	Subclass	Filing Date if Appropriate
Ge	5 4 8 6 2 0 4	01/23/96	Clifton			
Ge	6 0 9 0 7 7 5	07/18/00	Rothwell et al			
Ge	6 0 9 6 7 3 9	08/01/00	Feuerstein			
Ge	6 0 5 2 6 1 9	04/18/00	John			
Ge	5 5 2 7 8 2 2	06/18/96	Scheiner			
Ge	6 2 3 5 4 8 9	05/22/01	Jackowski			

COPY OF PAPER
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ge		Hermann et al., Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography, J. Neurotrauma, (2000) 17, 2, pp113-133.
Ge		Rothoerl et al., S-100 serum levels after minor and major head injury, J. Trauma, (1998) 45, 4, pp765-767.
Ge		Hermann et al., Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury, J. Neurol. Neurosurg. Psych., (2001) 70, 1, pp95-100.
Ge		Raabe et al., Correlation of computed tomography findings and serum brain damage markers following severe head injury, Acta. Neurochir. (Wein), (1998) 140, pp787-792.
Ge		Raabe and Seifert, Protein S-100B as a serum marker of brain damage in severe head injury: preliminary results, Neurosurg. Rev., (2000) 23, pp136-138.
Ge		Yamazaki et al., Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury, Surg. Neurol., (1995) 43, pp267-271.

EXAMINER

Gary Counts

DATE CONSIDERED

6/27/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce

(Rev. 8-83)

Patent and Trademark Office

Atty. Docket No.
2132.022Serial No.
09/940,698

INFORMATION DISCLOSURE CITATION

Applicant
Jackowski et al.Filing Date
08/27/2001Group
3736

(Use several sheets if necessary)

U. S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GC		Mao et al., (copy of English Abstract) The value of serum myelin basic protein in assessment of severity of acute closed head trauma (Chinese), Hua Xi Yi Ke Da Xue Bao, COPY OF PAGE 135-137.
GC		Thomas et al., Serum myelin basic protein assay in diagnosis and <u>prognosis of patients with head injury</u> , Lancet, (1978) 1, 8056, pp113-115.
GC		Skogseld et al., Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage, Acta Neurochir (Wein), (1992), 115, pp106-111.
GC		Fridriksson, et al., Serum neuron-specific enolase as a predictor of intracranial lesions in children with head trauma: A pilot study, Academic Emergency Medicine, (2000), 7, pp816-820.
GC		Ingebrigtsen, et al., Traumatic brain damage in minor head injury: Relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome, Neurosurgery, (1999) 45, 3, pp468-476.
GC		Brain Injury Association (excerpt), www.biaus.org
GC		Center for Disease Control (excerpt), http://www.cdc.gov/ncipe/dacrrdp/tbi.htm
GC		National Institute of Health (excerpt), http://nindsiis2.ninds.nih.gov

EXAMINER

Mary Gault

DATE CONSIDERED

6/27/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2132.022APPLICATION NO.
09/940,698**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
JACKOWSKI et al.FILING DATE
08/27/01GROUP
3736RECEIVED
JUL 23 2003**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

RECEIVED

JUL 18 2003

TECHNOLOGY CENTER R3700

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION

RECEIVED

JUL 23 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GC		Lamers et al., "Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders", Acta Neurologica Scandinavica (1995) Vol. 92, pp.247-251.
GC		Engelen et al., "Age-Related Changes of Neuron-Specific Enolase, S-100 Protein, and Myelin Basic Protein Concentrations in Cerebrospinal Fluid", Clinical Chemistry (1992) Vol. 28, No. 6, pp.813-816.

EXAMINER

Gary Counts

DATE CONSIDERED

6/27/05

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.